What BMI Do You Need for Semaglutide?
Last updated: June 2026
Semaglutide's weight-management label (Wegovy) sets the bar at a body mass index of 30 or higher — or 27 or higher if you also carry at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Those two numbers, 30 and 27, are the whole eligibility gate on paper, and the identical pair appears on the tirzepatide (Zepbound) and liraglutide (Saxenda) weight-loss labels.
Not sure which side of 27 or 30 you land on? Enter your height and weight and read your BMI to one decimal place.
Open the BMI calculator →TL;DR — key takeaways
- BMI ≥ 30 qualifies on its own. No second condition is required at or above the obesity line.
- BMI 27–29.9 qualifies only with a comorbidity. In the 27-to-30 band you also need at least one weight-related condition.
- The threshold is not drug-specific. Wegovy, Zepbound, and Saxenda all use the same 27/30 cut-offs — it is the standard obesity-medicine definition, not a semaglutide quirk.
- BMI is a moving weight target. Because BMI = weight ÷ height², the pounds that cross 27 or 30 depend entirely on your height.
- It is a screening number, not a verdict. A prescriber confirms the comorbidity and the clinical picture; BMI alone does not write a prescription.
Where the 27 and 30 come from
BMI is a single number that places your weight on a standard scale for your height. Public-health bodies have long drawn the same lines on that scale: the CDC and WHO both define a BMI of 25 to under 30 as overweight and 30 or above as obesity. Obesity is then split into class 1 (30–34.9), class 2 (35–39.9), and class 3 (40 and above).
When the FDA approved semaglutide for chronic weight management, the indication borrowed those exact public-health lines rather than inventing new ones. The pivotal STEP 1 trial enrolled adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related coexisting condition — and the label codified the same entry criteria. The tirzepatide SURMOUNT-1 trial used the matching cut-offs, which is why every drug in this class shares the threshold. The “27 with a condition” carve-out exists because someone who is overweight rather than obese but already has hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease carries elevated risk that the medication is meant to address.
BMI categories vs the prescribing threshold
| Category | BMI range | Eligibility per the weight-loss label |
|---|---|---|
| Healthy weight | 18.5–24.9 | Not indicated |
| Overweight (low) | 25.0–26.9 | Not indicated for weight management |
| Overweight (high) | 27.0–29.9 | Eligible only with ≥1 weight-related condition |
| Obesity, class 1 | 30.0–34.9 | Eligible on BMI alone |
| Obesity, class 2 | 35.0–39.9 | Eligible on BMI alone |
| Obesity, class 3 | 40.0 and above | Eligible on BMI alone |
Notice the only conditional row is 27–29.9. Below 27 the weight-loss label does not apply; at 30 and above, the BMI alone meets the criterion.
The threshold drawn on a number line
Eligibility is easier to see as a ruler. Everything left of 27 is outside the weight-loss indication, the amber 27–30 band is the “needs a condition” zone, and the teal stretch from 30 upward qualifies on BMI alone.
What 27 and 30 mean in pounds
Because the cut-off is a BMI value, the weight that crosses it shifts with height. The chart below gives the weight at which each height reaches BMI 27 and BMI 30 (rounded to the nearest pound). Below the BMI-27 weight you are outside the indication; between the two weights you are in the conditional band; at or above the BMI-30 weight you meet the criterion on BMI alone.
| Height | Weight at BMI 27 | Weight at BMI 30 |
|---|---|---|
| 5'2" (62 in) | 148 lb | 164 lb |
| 5'4" (64 in) | 157 lb | 175 lb |
| 5'6" (66 in) | 167 lb | 186 lb |
| 5'8" (68 in) | 178 lb | 197 lb |
| 5'10" (70 in) | 188 lb | 209 lb |
| 6'0" (72 in) | 199 lb | 221 lb |
| 6'2" (74 in) | 210 lb | 234 lb |
The gap between the two columns is the conditional band: land there and your eligibility depends on having a weight-related condition documented by your clinician.
Worked examples
BMI in metric units is weight in kilograms divided by height in metres squared. In US units it is 703 × weight in pounds ÷ height in inches squared. The 703 factor simply converts the imperial figures onto the same scale.
Example 1 — metric, conditional band
92 kg at 1.78 m. 1.78² = 3.168. 92 ÷ 3.168 = BMI 29.0.
That is in the 27–30 band — eligible only with a documented weight-related condition.
Example 2 — US units, qualifies on BMI alone
230 lb at 5'8" (68 in). 68² = 4,624. 703 × 230 ÷ 4,624 = BMI 35.0.
That is class 2 obesity — eligible on BMI alone, no second condition needed.
Example 3 — finding the BMI-30 weight
At 5'9" (69 in), the weight for BMI 30 is 30 × 69² ÷ 703 = 30 × 4,761 ÷ 703 = 203 lb.
So a 5'9" adult crosses into obesity at roughly 203 lb.
Example 4 — finding the BMI-27 weight
Same 5'9" height, BMI 27: 27 × 4,761 ÷ 703 = 183 lb.
Between 183 lb and 203 lb at 5'9", you are in the conditional band; below 183 lb you fall outside the weight-loss indication.
Example 5 — just over the lower line
158 lb at 5'4" (64 in). 64² = 4,096. 703 × 158 ÷ 4,096 = BMI 27.1.
Barely into the conditional band — a single pound or two of measurement error can move you across 27, which is why a careful height and weight matter.
Example 6 — how close the lines sit
215 lb at 5'10" (70 in) is 703 × 215 ÷ 4,900 = BMI 30.8. The BMI-30 weight at this height is 209 lb.
Only about 6 lb separates this person from the conditional band — category boundaries are narrow, so round honestly.
How this is calculated
Every number on this page comes from one formula: BMI = weight (kg) ÷ height (m)², or equivalently 703 × weight (lb) ÷ height (in)². The weight thresholds in the chart are that formula rearranged — weight = BMI × height² ÷ 703 — solved at BMI 27 and BMI 30 for each height, then rounded to the nearest pound. There is no drug-specific constant anywhere in this; semaglutide, tirzepatide, and liraglutide all sit on the same BMI ruler. The InjectBuddy BMI calculator runs exactly this arithmetic and tells you which band you fall in. This is the maths behind an eligibility rule, not medical advice: the presence of a qualifying weight-related condition, and the decision to prescribe, are clinical judgements your prescriber makes.
Frequently asked questions
Does a BMI of 27 guarantee I will be prescribed semaglutide?
No. A BMI of 27–29.9 only meets the label criterion if you also have a documented weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Even then, prescribing is a clinical decision, not an automatic outcome of the number.
Is the BMI cut-off different for Ozempic?
Ozempic is the type 2 diabetes label for semaglutide and is indicated by a diabetes diagnosis, not a BMI threshold. Wegovy is the weight-management label, and that is the one tied to the 27/30 BMI criteria described here.
What counts as a weight-related condition?
The labels give examples including high blood pressure, type 2 diabetes, high cholesterol or other dyslipidemia, obstructive sleep apnea, and cardiovascular disease. Your clinician confirms whether a qualifying condition is present.
Do teenagers use the same BMI number?
No. For adolescents aged 12 and older, the pediatric criterion is a BMI at or above the 95th percentile for age and sex, not the fixed adult value of 30. Childhood BMI is read against growth charts, so a single threshold number does not apply.
Sources
- WEGOVY (semaglutide injection) Prescribing Information (DailyMed / FDA label) — indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity
- ZEPBOUND (tirzepatide injection) Prescribing Information (DailyMed / FDA label) — same BMI ≥30 / ≥27-with-comorbidity weight-management criteria
- SAXENDA (liraglutide injection) Prescribing Information (DailyMed / FDA label) — chronic weight management at BMI ≥30, or ≥27 with a weight-related comorbid condition
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (N Engl J Med 2021) — enrolled BMI ≥30, or ≥27 with ≥1 weight-related condition
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (N Engl J Med 2022) — BMI ≥30, or ≥27 with a weight-related complication
- CDC — Adult BMI Categories (underweight <18.5, healthy 18.5–<25, overweight 25–<30, obesity ≥30)
- World Health Organization — Obesity and overweight fact sheet (overweight BMI ≥25, obesity BMI ≥30)
- NHLBI (NIH) — Calculate Your Body Mass Index (BMI formula and adult categories)
This guide is for general educational purposes only and does not constitute medical advice. Always follow your prescriber’s specific instructions and consult a qualified clinician before changing any protocol.